Clinical Trials
21 trialsNCT07216703 2026-06-01
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04977453 2026-05-15
Keynote B59
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT04389632 2026-05-11
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT05581004 2026-05-11
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06266338 2026-05-06
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT06157151 2026-04-23
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen, Inc
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT07227168 2026-03-05
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
Phase 1 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05082259 2026-02-10
ASTEROID
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT07054567 2026-01-21
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT06640283 2025-12-24
ANA
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04865887 2025-10-07
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Georgetown University
Phase 2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03476681 2025-04-24
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics, Inc
Phase 1/2 Recruiting
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT06265025 2024-03-21
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
Phase 1/2 Recruiting
NCT06022757 2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2 Recruiting